DK1737966T3 - Cancerspecifik promotorer - Google Patents
Cancerspecifik promotorerInfo
- Publication number
- DK1737966T3 DK1737966T3 DK05767457.4T DK05767457T DK1737966T3 DK 1737966 T3 DK1737966 T3 DK 1737966T3 DK 05767457 T DK05767457 T DK 05767457T DK 1737966 T3 DK1737966 T3 DK 1737966T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- specific
- control sequences
- specific control
- combination
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 206010006187 Breast cancer Diseases 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 2
- 206010060862 Prostate cancer Diseases 0.000 abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 2
- 201000002528 pancreatic cancer Diseases 0.000 abstract 2
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 102000007238 Transferrin Receptors Human genes 0.000 abstract 1
- 108010033576 Transferrin Receptors Proteins 0.000 abstract 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 abstract 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 230000001124 posttranscriptional effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70582—CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55911104P | 2004-04-02 | 2004-04-02 | |
| PCT/US2005/011067 WO2005103251A2 (en) | 2004-04-02 | 2005-04-01 | Cancer specific promoters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1737966T3 true DK1737966T3 (da) | 2012-07-09 |
Family
ID=35057078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05767457.4T DK1737966T3 (da) | 2004-04-02 | 2005-04-01 | Cancerspecifik promotorer |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7816131B2 (da) |
| EP (1) | EP1737966B1 (da) |
| JP (1) | JP2007535315A (da) |
| CN (1) | CN1997745A (da) |
| AT (1) | ATE557094T1 (da) |
| DK (1) | DK1737966T3 (da) |
| ES (1) | ES2385492T3 (da) |
| PT (1) | PT1737966E (da) |
| WO (1) | WO2005103251A2 (da) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
| US7709253B2 (en) * | 2006-08-04 | 2010-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists |
| WO2008070448A2 (en) * | 2006-11-22 | 2008-06-12 | Board Of Regents, The University Of Texas System | Cancer-specific promoters |
| JP5731198B2 (ja) | 2007-09-27 | 2015-06-10 | イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用 |
| AU2009253780B2 (en) | 2008-06-05 | 2014-08-14 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| WO2010097419A1 (en) | 2009-02-25 | 2010-09-02 | Fundació Privada Centre De Regulació Genòmica (Crg) | Conditionally replicating adenovirus effective in the treatment of tumors |
| WO2010114143A1 (ja) * | 2009-03-30 | 2010-10-07 | 国立大学法人岡山大学 | 特異的プロモーターの活性を上昇させるシステム及び該システムを保持したベクター |
| WO2012043710A1 (ja) * | 2010-09-30 | 2012-04-05 | 国立大学法人 鹿児島大学 | Auroraキナーゼプロモーターを含む増殖制御型ウイルスベクター |
| EP2655636B1 (en) * | 2010-12-24 | 2015-04-22 | Agency For Science, Technology And Research | Modified cmv promoters that are resistant to gene silencing |
| CN102352369A (zh) * | 2011-07-06 | 2012-02-15 | 中山大学肿瘤防治中心 | 一种在肿瘤细胞中高效高特异表达靶基因的载体t-visa |
| CN102327624A (zh) * | 2011-09-28 | 2012-01-25 | 中山大学肿瘤防治中心 | 一种可高效在体内外转染基因的新型脂质体及其制备方法 |
| CN113876945A (zh) | 2011-10-06 | 2022-01-04 | 免疫疫苗技术有限公司 | 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用 |
| CN102716498A (zh) * | 2012-03-12 | 2012-10-10 | 中山大学肿瘤防治中心 | 一种可高效高特异灭杀p53基因突变型乳腺癌细胞的药物脂质体 |
| EP3003393A4 (en) | 2013-06-04 | 2017-01-11 | The Johns Hopkins University | Tripartite cancer theranostic nucleic acid constructs |
| EP3004357A4 (en) | 2013-06-04 | 2017-01-11 | The Johns Hopkins University | Peg-prom mediated surface expression of avidin/streptavidin |
| EP3004872B1 (en) | 2013-06-04 | 2017-10-18 | Virginia Commonwealth University | Mda-9/syntenin promoter to image and treat metastatic cancer cells |
| EP3004153B1 (en) | 2013-06-04 | 2019-10-30 | Virginia Commonwealth University | Recombinant cancer therapeutic cytokine |
| WO2014209553A1 (en) | 2013-06-04 | 2014-12-31 | Virginia Commonwealth University | Use of a truncated ccn1 promoter for cancer diagnostics, therapeutics and theranostics |
| US10412939B2 (en) * | 2015-09-02 | 2019-09-17 | Regeneron Pharmaceuticals, Inc. | Rodent model of prostate cancer |
| JOP20190166A1 (ar) * | 2017-01-05 | 2019-07-02 | Univ Texas | استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي |
| US12233135B2 (en) | 2018-04-11 | 2025-02-25 | Precision Molecular Inc. | Therapeutic constructs for treating cancer |
| AR119271A1 (es) | 2019-06-11 | 2021-12-09 | Shire Human Genetic Therapies | Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada |
| JP7659550B2 (ja) | 2019-10-23 | 2025-04-09 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療 |
| EP4263614A1 (en) | 2020-12-16 | 2023-10-25 | Takeda Pharmaceutical Company Limited | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| AUPO492397A0 (en) | 1997-02-03 | 1997-02-27 | Commonwealth Scientific And Industrial Research Organisation | Prostate specific promoters |
| AU5742198A (en) | 1997-02-03 | 1998-08-25 | Commonwealth Scientific And Industrial Research Organisation | Tissue specific promoters |
| GB9703633D0 (en) | 1997-02-21 | 1997-04-09 | Imp Cancer Res Tech | Cancer therapy |
| WO1999016787A1 (en) | 1997-09-26 | 1999-04-08 | Washington University | Cell death agonists |
| US6313373B1 (en) | 1998-10-30 | 2001-11-06 | Case Western Reserve University | Tissue specific promoters and transgenic mouse for the screening of pharmaceuticals |
| US6716824B1 (en) * | 1999-10-22 | 2004-04-06 | F. Charles Brunicardi | Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy |
| JP2001218587A (ja) | 2000-02-08 | 2001-08-14 | Academia Sinica | 最小ｃｍｖプロモーターを含むバキュロウイルス |
| JP2003535593A (ja) | 2000-06-06 | 2003-12-02 | ジェネラブス テクノロジーズ，インコーポレイテッド | 調節された遺伝子発現のためのプロモーター |
| EP1207204A1 (de) | 2000-11-16 | 2002-05-22 | KWS Saat AG | Gewebespezifische Promotoren aus der Zuckerrübe |
| DE10209451A1 (de) | 2002-03-05 | 2003-09-18 | Universitaetsklinikum Hamburg | Spezifische Genexpression in Kolonkarzinom-Zell-Linien |
| CN100497382C (zh) * | 2003-04-02 | 2009-06-10 | 得克萨斯州大学系统董事会 | 突变型Bik的抗肿瘤效果 |
-
2005
- 2005-04-01 PT PT05767457T patent/PT1737966E/pt unknown
- 2005-04-01 WO PCT/US2005/011067 patent/WO2005103251A2/en not_active Ceased
- 2005-04-01 CN CNA2005800119931A patent/CN1997745A/zh active Pending
- 2005-04-01 DK DK05767457.4T patent/DK1737966T3/da active
- 2005-04-01 EP EP05767457A patent/EP1737966B1/en not_active Expired - Lifetime
- 2005-04-01 US US11/096,622 patent/US7816131B2/en not_active Expired - Fee Related
- 2005-04-01 AT AT05767457T patent/ATE557094T1/de active
- 2005-04-01 JP JP2007506305A patent/JP2007535315A/ja not_active Withdrawn
- 2005-04-01 ES ES05767457T patent/ES2385492T3/es not_active Expired - Lifetime
-
2007
- 2007-01-24 US US11/626,655 patent/US7723104B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1997745A (zh) | 2007-07-11 |
| US20050260643A1 (en) | 2005-11-24 |
| WO2005103251A2 (en) | 2005-11-03 |
| JP2007535315A (ja) | 2007-12-06 |
| PT1737966E (pt) | 2012-08-06 |
| WO2005103251A3 (en) | 2006-04-27 |
| US7816131B2 (en) | 2010-10-19 |
| US20080286860A1 (en) | 2008-11-20 |
| US7723104B2 (en) | 2010-05-25 |
| EP1737966B1 (en) | 2012-05-09 |
| ES2385492T3 (es) | 2012-07-25 |
| ATE557094T1 (de) | 2012-05-15 |
| EP1737966A2 (en) | 2007-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1737966T3 (da) | Cancerspecifik promotorer | |
| MX2019015200A (es) | Compuestos de diarilhidantoina. | |
| PH12019501959A1 (en) | Therapeutic rna | |
| MX2009008132A (es) | Terapia de combinacion con inhibidores de angiogenesis. | |
| MX2010003658A (es) | Sistema quirurgico no invasivo basado en fotones que incluye control celular automatico y erradicacacion por control de proalimentacion pre-calculada mas control de retroalimentacion de imagen para suministro enfocado de energia. | |
| SG170809A1 (en) | Diarylthiohydantoin compounds | |
| NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
| MY183404A (en) | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors | |
| BR112013029212A2 (pt) | anticorpos para o tratamento de câncer expressando claudina-6 | |
| GEP20125647B (en) | Kinesin inhibitors as cancer therapeutics | |
| ZA202106392B (en) | Therapeutic rna for prostate cancer | |
| WO2005116259A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
| IN2012DN05143A (da) | ||
| WO2010054397A3 (en) | N-cadherin: target for cancer diagnosis and therapy | |
| MX2010008994A (es) | Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario. | |
| WO2008134752A3 (en) | Methods and compositions for the treatment of cancer | |
| WO2008070448A3 (en) | Cancer-specific promoters | |
| MX2021012931A (es) | Polipeptidos multiespecificos activables y terapeuticos con semivida extendida. | |
| NZ589795A (en) | Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis | |
| WO2009038771A3 (en) | Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers | |
| WO2008144659A3 (en) | Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers | |
| ATE443138T1 (de) | Hemmung der expression von spag9 mit sirnas | |
| TH105533B (th) | พาราพ็อกซ์ไวรัสร่วมกันกับสารเคมีบำบัดที่เป็นพิษต่เซลล์ดั้งเดิมเป็นการรักษาทางชีวเคมีสำหรับการบำบัดมะเร็ง | |
| UA35392U (ru) | Способ комплексной терапии злокачественных опухолей и метастазов | |
| TN2009000491A1 (en) | Use of heterosidic flavonoid derivatives for therapy of stem cell cancers |